Is Sermorelin FDA Approved? What the Regulatory History Actually Shows
Sermorelin was FDA-approved in 1997 as the brand-name drug Geref, for growth hormone deficiency. The manufacturer withdrew it from sale in 2008 for business reasons, not safety findings. Today’s sermorelin is a compounded, prescription-only preparation, and compounded products are not individually FDA-approved.
The short answer
Neither “sermorelin is FDA-approved” nor “sermorelin was never approved” is accurate. Both get repeated online, and both miss the actual history.
The molecule did go through FDA approval. Geref, sermorelin acetate injection, was approved in 1997 to diagnose and treat growth hormone deficiency in children. The manufacturer, EMD Serono, discontinued the commercial product in 2008. The FDA later confirmed, in a formal 2013 determination, that Geref was not pulled for safety or effectiveness reasons.
What exists now is different. Sermorelin is supplied through compounding pharmacies, under a prescription, for an individual patient. A compounded preparation is not the same regulatory category as a manufactured, FDA-approved drug, no matter what the original brand-name product’s history was.
What actually happened to Geref
Sermorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue. It does not contain growth hormone. It signals the pituitary gland to release the growth hormone the body already makes. That distinction is worth holding onto, because it is also why sermorelin and HGH get confused and are not interchangeable.
As Geref, sermorelin cleared FDA review with clinical trial data behind it, for a specific pediatric indication. That is the part of the story most sourcing pages skip. It was not a supplement or a research chemical that slipped past regulation. It went through the same premarket approval pathway as any prescription drug.
EMD Serono discontinued Geref in 2008. When a company stops selling an approved drug, other manufacturers can ask the FDA whether it was withdrawn for safety reasons, because that determination affects whether a generic version can reference the original approval. In 2013, the FDA answered that question for Geref directly: it was not withdrawn for reasons of safety or effectiveness. Low commercial demand ended the product, not a finding against it.
That is a meaningfully different story than a drug pulled after adverse events. It is also not the same as an active, current FDA approval. Both facts are true at once, and a clinic or vendor that only states one of them is giving you half the picture.
What “compounded” means for the sermorelin you’d actually receive
Once Geref left the market, sermorelin did not disappear. It moved to compounding pharmacies, which can prepare it under a licensed prescriber’s order. That is standard, legal practice, and it is how a wide range of medications reach patients when a commercial version is unavailable or doesn’t fit a specific need.
It also means something specific for FDA status. Compounded medications are not individually reviewed by the FDA for safety, effectiveness, or quality before they reach a patient, regardless of whether the original molecule once carried an approval. That responsibility sits with the compounding pharmacy and the prescriber instead. We cover how that oversight structure works, and what separates a well-run compounder from a risky one, in our piece on 503A versus 503B compounding pharmacies.
This is also where the sourcing question stops being academic. A live search for sermorelin turns up no shortage of vendors selling it as a “research use only” vial, sold without a prescription and outside any pharmacy oversight at all. That is a different product category from a compounded medication dispensed against a prescription. Neither is FDA-approved in the retail-drug sense, but only one of them has a licensed pharmacy and a prescriber standing behind it.
What to ask before starting sermorelin
The FDA-approval question turns out to be the wrong first question. The more useful ones are about sourcing and oversight.
Ask whether sermorelin is prescribed only after a real evaluation, not sold as a standing order. Ask which compounding pharmacy supplies it, and whether that provider is willing to name it plainly rather than describe a “proprietary formula.” Our sermorelin therapy page covers how this clinic handles prescribing and evaluation for this specific service.
Ask how response is monitored. Because sermorelin works by signaling the pituitary rather than supplying growth hormone directly, the practical way to see whether it’s working is a blood marker called IGF-1, insulin-like growth factor 1. The liver produces IGF-1 in response to growth hormone activity, and its levels stay fairly stable day to day, which is why it is used as a proxy for growth hormone output rather than measuring growth hormone itself. A clinician tracking IGF-1 over time, rather than guessing from how you feel, is a sign of the treatment being managed rather than dispensed.
Our broader peptide therapy page walks through where sermorelin fits among the peptides discussed in this space and what evaluation looks like before starting.
When to talk to a clinician
When to talk to a clinician
Talk to a clinician if you notice persistent injection-site redness, swelling, or pain that doesn’t improve within a day or two, unexpected headaches, joint pain, or fluid retention after starting sermorelin, or if a vendor cannot or will not tell you where a product is compounded.
Go to an emergency room for signs of a severe allergic reaction, difficulty breathing, swelling of the face or throat, or chest pain following any injection, regardless of what was administered or by whom.
Frequently asked questions
Is sermorelin FDA approved?
Sermorelin was FDA-approved in 1997 under the brand name Geref, for growth hormone deficiency in children. The manufacturer discontinued it in 2008, and the FDA later confirmed that withdrawal was for business reasons, not safety or effectiveness. Sermorelin is now available only as a compounded, prescription-only preparation, and compounded medications are not individually FDA-approved.
What is IGF-1?
IGF-1, insulin-like growth factor 1, is a hormone the liver produces in response to growth hormone activity. Because sermorelin works by prompting the pituitary to release growth hormone rather than supplying it directly, clinicians use IGF-1 blood levels to gauge whether that signal is having an effect, rather than relying on symptoms alone.
Is sermorelin the same as HGH?
No. Sermorelin is a growth hormone-releasing hormone analogue. It signals the pituitary gland to release the growth hormone your body already produces. HGH is growth hormone itself, given directly. They act on the body differently and are regulated differently, and the two terms should not be used interchangeably.
Can I buy sermorelin without a prescription?
It is sold that way online, typically labeled “research use only,” through vendors outside any pharmacy or prescriber oversight. That labeling does not make the product exempt from being a drug, and it removes the layer of prescriber evaluation and pharmacy accountability that a legitimately compounded, prescription-only product has behind it.
Sources
- Federal Register / U.S. Food and Drug Administration — Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- U.S. Food and Drug Administration — Compounding and the FDA: Questions and Answers
- National Institutes of Health / PMC — Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports
Not sure whether IV therapy is right for you?
Every drip here is ordered under a Florida-licensed medical director and placed by a registered nurse. Tell us what is going on and a nurse reads it and calls you back, including when the honest answer is that you do not need us.
Or call (941) 588-7770. A nurse answers, not a booking bot.